Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
13 avr. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial Results
14 mars 2016 08h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference on March 8th
02 mars 2016 17h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Rockwell Medical Enters Into Exclusive License Agreement With Wanbang Biopharmaceutical Co., Ltd. to Commercialize Triferic® in China
16 févr. 2016 08h00 HE
|
Rockwell Medical, Inc.
WIXOM, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
Proteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8th
02 févr. 2016 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients...
Proteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9th
02 déc. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2015 Healthcare Conference on November 17th
13 nov. 2015 07h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2015 Financial Results
12 nov. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
-Enrollment in PATENCY-1 Completed Ahead of Schedule-
-Data from PATENCY-1 Expected in December 2016-
-Proteon to Hold Research and Development Day in New York on November 20-
WALTHAM, Mass.,...
Proteon Therapeutics to Host Research and Development Day on November 20, 2015
09 nov. 2015 11h58 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase
02 nov. 2015 16h15 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...